NRDL China: 2024 outlook

Published on August 10, 2024

Heightened budget pressure, increasing competitions and ongoing fine-tuning of the value rating system: NRDL gets tougher this year.

2024 NRDL has been unfolding very much as planned: A total of 574 drug candidates went into the National Reimbursement Drug List (NRDL) formal review process in June, and 445 of them passed the formal review in August, a record high since 2021. Among those, 249 are seeking their initial listing, while 196 are up for renewal or re-negotiations. 

 

It will not be a smooth ride for all to make it to the final though, given the heightened budget pressure, increasing competition and ongoing fine-tuning of the listing criteria, including the value rating system introduced last year. The first revelation came in September after tallying the outcomes of expert review process, as less than half of those seeking initial listing made it to the shortlist for negotiation, compared to 64% in 2023 and 67% in…

NRDL Outlook China

Continue reading on website
Other news

Iniciativas RGM: prioridades 2025 y el próximo horizonte - México

August 9, 2024
La dinámica inflacionaria, la menor confianza del consumidor y las presiones de tipo de cambio y tasas de interés plantean un escenario desafiante para las empresas de consumo masivo en América Latina. En este contexto es crucial que adaptemos nuestra estrategia comercial y desarrollemos nuevas herramientas y capacidades para maximizar el potencial de crecimiento de nuestras organizaciones.  Quere

Navigating the new era of B2B sales

August 10, 2024